Cargando…

High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families

BACKGROUND: Germline mutations in the tumour suppressor gene CDKN2A occur in 5–20% of familial melanoma cases. A single founder mutation, p.Arg112dup, accounts for the majority of CDKN2A mutations in Swedish carriers. In a national program, carriers of p.Arg112dup mutation have been identified. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Helgadottir, Hildur, Höiom, Veronica, Jönsson, Göran, Tuominen, Rainer, Ingvar, Christian, Borg, Åke, Olsson, Håkan, Hansson, Johan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Cancer Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112445/ https://www.ncbi.nlm.nih.gov/pubmed/24935963 http://dx.doi.org/10.1136/jmedgenet-2014-102320

Ejemplares similares

Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations
por: Helgadottir, Hildur, et al.
Publicado: (2020)

The genetics of uveal melanoma: current insights
por: Helgadottir, Hildur, et al.
Publicado: (2016)

Multiple Primary Melanoma Incidence Trends Over Five Decades: A Nationwide Population-Based Study
por: Helgadottir, Hildur, et al.
Publicado: (2020)

Melanoma‐specific survival before and after inclusion in a familial melanoma dermatologic surveillance program in CDKN2A mutation carriers and non‐carriers
por: Pissa, Maria, et al.
Publicado: (2022)

Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non‐CDKN2A/CDK4 melanoma families
por: Potjer, Thomas P., et al.
Publicado: (2019)

Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions
por: Barrett, Jennifer H, et al.
Publicado: (2015)

Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status
por: Das, Ishani, et al.
Publicado: (2019)

The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma
por: Lesueur, F, et al.
Publicado: (2008)

Association between a 46-SNP Polygenic Risk Score and melanoma risk in Dutch patients with familial melanoma
por: Potjer, Thomas P, et al.
Publicado: (2021)

Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants
por: Spagnolo, Francesco, et al.
Publicado: (2021)

Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants
por: Puntervoll, Hanne Eknes, et al.
Publicado: (2013)

Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors
por: Costa Svedman, Fernanda, et al.
Publicado: (2022)

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma
por: Vidarsdottir, Linda, et al.
Publicado: (2021)

Search for germline alterations in CDKN2A/ARF and CDK4 of 42 Jewish melanoma families with or without neural system tumours
por: Marian, C, et al.
Publicado: (2005)

AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma
por: Das, Ishani, et al.
Publicado: (2020)

Surveillance, CDKN2A and survival of familial melanoma
por: van Doorn, Remco
Publicado: (2023)

Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment
por: Helgadottir, Hildur, et al.
Publicado: (2018)

Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns
por: Holm, Karolina, et al.
Publicado: (2010)

Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma
por: Costa Svedman, Fernanda, et al.
Publicado: (2022)

Tumor genetic heterogeneity analysis of chronic sun‐damaged melanoma
por: Sanna, Adriana, et al.
Publicado: (2019)

Linkage and association analysis of nevus density and the region containing the melanoma gene CDKN2A in UK twins
por: Barrett, J H, et al.
Publicado: (2003)

Population-based analysis of POT1 variants in a cutaneous melanoma case–control cohort
por: Simonin-Wilmer, Irving, et al.
Publicado: (2023)

High expression of ZNF703 independent of amplification indicates worse prognosis in patients with luminal B breast cancer
por: Reynisdottir, Inga, et al.
Publicado: (2013)

Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells
por: Azimi, Alireza, et al.
Publicado: (2017)

The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response
por: Cabrita, Rita, et al.
Publicado: (2020)

Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study)
por: Naeser, Ylva, et al.
Publicado: (2022)

NF1‐mutated melanoma tumors harbor distinct clinical and biological characteristics
por: Cirenajwis, Helena, et al.
Publicado: (2017)

Alternative splicing and ACMG-AMP-2015-based classification of PALB2 genetic variants: an ENIGMA report
por: Lopez-Perolio, Irene, et al.
Publicado: (2019)

Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma
por: Mitra, Shamik, et al.
Publicado: (2020)

Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study
por: Helgadottir, Hildur, et al.
Publicado: (2023)

Familial risk of epithelial ovarian cancer after accounting for gynaecological surgery: a population-based study
por: Barnard, Mollie E, et al.
Publicado: (2023)

MLL3 regulates the CDKN2A tumor suppressor locus in liver cancer
por: Zhu, Changyu, et al.
Publicado: (2023)

A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects
por: Jervis, Sarah, et al.
Publicado: (2015)

Molecular and genetic diversity in the metastatic process of melanoma
por: Harbst, Katja, et al.
Publicado: (2014)

Correlation of histopathologic characteristics to protein expression and function in malignant melanoma
por: Welinder, Charlotte, et al.
Publicado: (2017)

Epigenetic Characterization of CDKN1C in Placenta Samples from Non-syndromic Intrauterine Growth Restriction
por: López-Abad, Miriam, et al.
Publicado: (2016)

Establishing a Southern Swedish Malignant Melanoma OMICS and biobank clinical capability
por: Welinder, Charlotte, et al.
Publicado: (2013)

Association of MC1R Variants and Host Phenotypes With Melanoma Risk in CDKN2A Mutation Carriers: A GenoMEL Study
por: Demenais, F., et al.
Publicado: (2010)

Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance
por: Kimura, Hirokazu, et al.
Publicado: (2022)

A BAP1 Mutation in a Danish Family Predisposes to Uveal Melanoma and Other Cancers
por: Aoude, Lauren G., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_a6ggi9nj3nkuppv94q5903t6p3